Evidence map›Paper›PMID 40047007›Full record

ArticlePsychedelic medicine (New Rochelle, N.Y.)2023

Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice.

Jacob S Aday, Zachary Skiles, Noa Eaton, Lisa Fredenburg, Mollie Pleet, Jessica Mantia, Ellen R Bradley, Gisele Fernandes-Osterhold, Joshua D Woolley

Abstract read
In one paragraph

Article in Psychedelic medicine (New Rochelle, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jacob S AdayDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-0578-8530
Zachary SkilesVA Portland Health Care System, Portland, Oregon, USA.
Noa EatonDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California, USA.
Lisa FredenburgDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California, USA.
Mollie PleetDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California, USA.
Jessica MantiaDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California, USA.
Ellen R BradleyDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California, USA.
Gisele Fernandes-OsterholdDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California, USA.
Joshua D WoolleyDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California, USA.

Funding

CSRD VA IK4 CX002090
6 · The paper itself

Abstract

Background: An emerging controversy in psychedelic therapy regards the appropriateness or necessity of psychedelic therapists having personal experience using psychedelics themselves. Although there are a number of potential advantages and disadvantages to personal use among psychedelic therapists, no studies to date have measured their use or other aspects of their training. Materials and Methods: First, we broadly review the literature on experiential learning in psychotherapy and psychiatry as well as the history of personal use of psychedelics by professionals. We then report on the results of a survey that was sent to all 145 therapists associated with Usona Institute's Phase II clinical trial of psilocybin for major depressive disorder. Thirty-two of these individuals (22% response rate) participated in the survey. Results: We found that experiential learning is common in psychotherapy but not in psychiatry, meaning psychedelic therapy straddles two different traditions. In our survey, the majority of psychedelic therapists identified as white, female, and having doctoral degrees. Most of the sample had personal experience with at least one serotonergic psychedelic (28/32; 88%), with psilocybin being most common (26/32; 81%; median number of uses = 2-10; median last use 6-12 months before survey). Participants had myriad intentions for using psychedelics (e.g., personal development, spiritual growth, fun, curiosity). All respondents endorsed favorable views regarding the efficacy of psilocybin therapy. Conclusion: Personal experience with psychedelics was notably common in this sample of psychedelic therapists, but the study was limited by a low response rate and a lack of diversity among participants. Future research is needed to address these limitations as well as to identify whether personal experience with psychedelics contributes to therapists' competency or introduces bias to the field. Nonetheless, these findings are the first to delineate the personal use of psychedelics among professionals and can inform a pressing debate for the field.

Indexed as

experiential learningfacilitatorspersonal experiencepsychedelic-assisted psychotherapypsychedelicspsychedelic therapists

Identifiers

PMID40047007
PMCPMC11658662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.